Trial reportThe Journal of membrane biology2012
Regulation of connexin43 gap junction protein triggers vascular recovery and healing in human ocular persistent epithelial defect wounds.
Trial report in The Journal of membrane biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 80 citations in OpenAlex.
- Exploratory Phase II Multicenter, Open-Label, Clinical Trial of ST266, a Novel Secretome for Treatment of Persistent Corneal Epithelial Defects.Translational vision science & technology · 2022Trial
- Repair of Corneal Epithelial Defects.Progress in molecular and subcellular biology · 2026Review
- Emerging Treatments for Persistent Corneal Epithelial Defects.Vision (Basel, Switzerland) · 2025Review
- Connexin 43 hemichannels and related diseases.Antibody therapeutics · 2024Review
- Pannexins in the musculoskeletal system: new targets for development and disease progression.Bone research · 2024Review
- Connexins in epidermal health and diseases: insights into their mutations, implications, and therapeutic solutions.Frontiers in physiology · 2024Review
- Gap Junctions or Hemichannel-Dependent and Independent Roles of Connexins in Fibrosis, Epithelial-Mesenchymal Transitions, and Wound Healing.Biomolecules · 2023Review
- Review
- New Pharmacological Approaches for the Treatment of Neurotrophic Keratitis.Frontiers in pharmacology · 2022Review
- Wound healing of the corneal epithelium: a review.Asian biomedicine : research, reviews and news · 2021Review
- The role of gap junctions in cell death and neuromodulation in the retina.Neural regeneration research · 2021Review
- Connexin therapeutics: blocking connexin hemichannel pores is distinct from blocking pannexin channels or gap junctions.Neural regeneration research · 2021Review
- Ocular Neuropathic Pain: An Overview Focusing on Ocular Surface Pains.Clinical ophthalmology (Auckland, N.Z.) · 2020Review
- Connexin43 hemichannel block protects against the development of diabetic retinopathy signs in a mouse model of the disease.Journal of molecular medicine (Berlin, Germany) · 2019Article
- Persistent Corneal Epithelial Defects: A Review Article.Medical hypothesis, discovery & innovation ophthalmology journal · 2019Review
- The Role of Connexin-43 in the Inflammatory Process: A New Potential Therapy to Influence Keratitis.Journal of ophthalmology · 2019Review
- Therapeutic strategies targeting connexins.Nature reviews. Drug discovery · 2018Review
- Intracellular oligonucleotide delivery using the cell penetrating peptide Xentry.Scientific reports · 2018Article
- Connexin Communication Compartments and Wound Repair in Epithelial Tissue.International journal of molecular sciences · 2018Review
- The Connexin Mimetic Peptide Gap27 and Cx43-Knockdown Reveal Differential Roles for Connexin43 in Wound Closure Events in Skin Model Systems.International journal of molecular sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transiently blocking the expression of the gap junction protein connexin43 using antisense oligodeoxynucleotides or blocking hemichannels with connexin mimetic peptides has been shown to significantly improve outcomes in a range of acute wound models. Less is known about their likely effects in nonhealing wounds. In the eye, prolonged inflammation and lack of epithelial recovery in nonhealing corneal epithelial wounds may lead to corneal opacity, blindness or enucleation. We report here the first human applications of antisense oligodeoxynucleotides that transiently block translation of connexin43 in a prospective study of five eyes with severe ocular surface burns (persistent epithelial defects), which were unresponsive to established therapy for 7 days to 8 weeks prior to treatment. Connexin43-specific antisense oligodeoxynucleotide was delivered in cold, thermoreversible Poloxamer407 gel under either an amniotic membrane graft or a bandage contact lens. The connexin43-specific antisense application reduced inflammation within 1-2 days, and in all five eyes complete and stable corneal reepithelialization was obtained. Recovery of the vascular bed and limbal reperfusion appeared to precede corneal epithelial recovery. We conclude that connexin modulation provides a number of benefits for nonhealing ocular burn wounds, one of which is to promote vascular recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.